Business Context and Reporting Period
Propanc Biopharma, Inc., a Delaware corporation with principal offices in Australia, filed this Form 8-K on December 7, 2021. The filing reports the entry into a material definitive agreement involving the issuance of a convertible promissory note to secure financing.
Key Financial Metrics
- Debt Instrument: Convertible promissory note with a principal amount of $170,000.
- Net Proceeds: $153,000 (after an original issue discount of $17,000).
- Interest Rate: 10% per annum (accruing to 24% upon certain events of default).
- Maturity Date: December 7, 2022.
- Use of Proceeds: General working capital purposes.
- Revenue/Profit/Cash Flow: The filing text does not provide a clear value for revenue, profit, or operating cash flow.
Material Changes and Transaction Details
The Company entered into a Securities Purchase Agreement with ONE44 Capital LLC. The note includes a conversion feature allowing the holder to convert principal into common stock starting June 5, 2022, at a price equal to 65% of the lowest closing bid price on the OTC Markets. Conversion is capped at 4.99% of outstanding shares to avoid registration requirements.
Prepayment terms include significant premiums depending on the timing of repayment:
- Within 60 days: 120% of face amount plus accrued interest.
- 60 to 120 days: 130% of face amount plus accrued interest.
- 120 to 180 days: 135% of face amount plus accrued interest.
Guidance, Risks, and Contingencies
The transaction is structured as a private placement under Section 4(a)(2) of the Securities Act and Regulation D. The Company covenants not to sell or dispose of substantially all assets without consent, which would render it a "shell company." Risks include potential dilution upon conversion and the obligation to pay high prepayment premiums if the debt is retired early. The interest rate accelerates to 24% upon the occurrence of specific default events, such as insolvency or failure to pay principal and interest.
Investor Verification Checklist
- Verify the closing date of the transaction (expected on or about December 13, 2021).
- Review the full text of the Securities Purchase Agreement and Convertible Promissory Note (Exhibits 10.1 and 4.1) for additional covenants.
- Monitor the Company's stock price on OTC Markets to assess potential dilution impact given the 65% conversion discount.
- Confirm the Company's current liquidity position to evaluate the ability to service the debt or meet prepayment terms.